EU Panel Recommends Approving Alexza's Adasuve

On Friday, Alexza Pharmaceuticals and Grupo Ferrer International, S.A., announced that Europe's Committee for Medicinal Products for Human Use (CHMP) has issued a "positive opinion" recommending that their Adasuve anti-agitation drug be approved for sale in the European Union.

Specifically, CHMP recommended that Adasuve be authorized in the EU for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder, provided the drug is "administered only in a hospital setting under the supervision of a health care professional" and that drugs be kept at hand to deal with possible severe respiratory side effects. CHMP's ruling was based on clinical trial results that showed "statistically significant reductions in agitation from baseline compared to placebo."

CHMP's recommendation is not binding, and will now go to the European Commission, which will render a binding decision, probably in the first quarter of next year.

Alexza estimates that as many as 8 million adults in the EU suffer from schizophrenia or bipolar disorder; agitation is a common symptom for those people.

Shares of Alexza are up nearly 10% on the news, at $5.75 per share.



The article EU Panel Recommends Approving Alexza's Adasuve originally appeared on

Fool contributor Rich Smith has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.